|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH Trial
|
Neil Fleshner, MD, MPH, FRCSC
Charles Ryan is joined by Neil Fleshner to discuss the efficacy and safety of radioligand 177Lu-PNT2002 in PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT) in the SPLASH trial.
|
|
|
|
|
|
|
|
|
|
|
| ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Fred Saad, MD, FRCS
Alicia Morgans and Fred Saad discuss the ongoing ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARANOTE is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. |
|
|
|
|
|
|
|
|
|
|
| Exercise Oncology in Prostate Cancer, A 2021 PCF-Pfizer Health Equity Challenge Award |
| Christina Dieli-Conwright, Ph.D., MPH |
| PCF-Pfizer Health Equity Challenge Award recipient Christina Dieli-Conwright joins Charles Ryan in a discussion on exercise oncology, particularly in prostate cancer. A field of research that is centered around the utilization of exercise or physical fitness to enhance the lives of people diagnosed with cancer or at risk of developing cancer. |
|
|
|
|
|
|
|
|
|
|
|
| First-in-Human Study of FOR46 in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) |
| Rahul Aggarwal, MD |
| Rahul Aggarwal joins Alicia Morgans describing this first-in-human study of the safety and preliminary efficacy of FOR46 in metastatic castration-resistant disease (mCRPC) patients. |
|
|
|
|
|
|
|
|
|
|
|
| CYCLONE 3: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk mHSPC
|
| Rana R. McKay, MD
|
| Rana McKay discusses the trial protocol for CYCLONE 3, a phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone + prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
|
|
|
|
|
| Open-Label Study of Androgen Receptor Inhibition With Darolutamide + ADT Versus ADT in Men With mHSPC Using an External Control Arm (ARASEC) |
| Neal D. Shore, MD, FACS |
| In this presentation, Neal Shore discusses the ARASEC study, an open-label study of androgen receptor inhibition with darolutamide + ADT versus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) using an external control arm. ARASEC will evaluate the efficacy and safety of darolutamide + ADT in mHSPC in the US and complement the data in the ongoing ARANOTE study. |
|
|
|
|
|
| Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer |
| Susan F. Slovin MD, Ph.D., FACP |
| Susan Slovin presents a poster on a phase 1 trial examining the use of P-PSMA-101, a chimeric antigen receptor T (CART) therapy targeting PSMA for men with advanced prostate cancer. P-PSMA-101 is an autologous CAR-T therapy targeting PSMA, with a high percentage of stem cell memory T cells (TSCM) associated with efficacy, safety, and bone homing (particularly relevant to prostate cancer). |
|
|
|
|
|
| PRIMORDIUM - A Randomized, International, Trial-in-Progress of Adding Apalutamide to Radiotherapy and an LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer |
| Boris Hadaschik, MD |
| Boris Hadaschik presents the PRIMORDIUM trial in progress, which specifically evaluates the benefit of adding the androgen receptor inhibitor apalutamide to testosterone suppression and radiotherapy in patients experiencing a “high-risk” biochemical recurrence after radical prostatectomy. |
|
|
|
|
|
| Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE): ECOG-ACRIN EA8191
|
| Neha Vapiwala, MD, FACR
|
| Neha Vapiwala presents the trial design of INDICATE, a study that will evaluate whether patients with PET-detected lesions benefit from such local or systemic treatment intensification approaches. The primary endpoint is PFS, defined as time from randomization to radiographic progression on conventional imaging, symptomatic disease or death. Primary objectives are to evaluate whether addition of apalutamide to standard of care salvage therapy and addition of metastasis-directed radiotherapy to standard of care salvage therapy and apalutamide could prolong PFS in Cohorts 1 and 2, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
